What is Laboratorios Farmaceuticos Rovi EV-to-EBITDA?
Laboratorios Farmaceuticos RoviLABFF 93 EV-to-EBITDA is 13.69 as of Jul. 11, 2026, which is 25% below its 10-year median of 18.25. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review. Among 739 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks worse than 53.59% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Laboratorios Farmaceuticos Rovi's enterprise value is $3,304.3 Mil.
Laboratorios Farmaceuticos Rovi's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $241.3 Mil. Therefore, Laboratorios Farmaceuticos Rovi's EV-to-EBITDA for today is 13.69.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's EV-to-EBITDA or its related term are showing as below:
LABFF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.52 Med: 18.25 Max: 42.73
Current: 14.03
During the past 13 years, the highest EV-to-EBITDA of Laboratorios Farmaceuticos Rovi was 42.73. The lowest was 6.52. And the median was 18.25.
LABFF's EV-to-EBITDA is ranked worse than 53.59% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.94
vs LABFF: 14.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Laboratorios Farmaceuticos Rovi's PE Ratio (TTM) for today is calculated as:
Laboratorios Farmaceuticos Rovi's share price for today is $90.61.
Laboratorios Farmaceuticos Rovi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's EV-to-EBITDA falls into.
Laboratorios Farmaceuticos Rovi's current Enterprise Value is $3,304.3 Mil.
Laboratorios Farmaceuticos Rovi's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $241.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (LABFF) has a EV-to-EBITDA of 13.69 as of Jul. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Laboratorios Farmaceuticos Rovi. This is 25% below median its historical median of 18.25. Over the past decade, Laboratorios Farmaceuticos Rovi's EV-to-EBITDA has ranged from 6.52 to 42.73. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #396 out of 739 companies in the Drug Manufacturers industry, placing it in the top 53.6%.
Is Laboratorios Farmaceuticos Rovi's EV-to-EBITDA too high?
Laboratorios Farmaceuticos Rovi's current EV-to-EBITDA of 13.69 is 25% below median its 10-year median of 18.25. Over the past 10 years, this metric has ranged from a low of 6.52 to a high of 42.73. The Drug Manufacturers industry median EV-to-EBITDA is 12.94. Laboratorios Farmaceuticos Rovi's value of 13.69 is 5.8% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #396 out of 739 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #396 out of 739 companies for EV-to-EBITDA. This places Laboratorios Farmaceuticos Rovi in the lower half of its industry. The industry median EV-to-EBITDA is 12.94. Laboratorios Farmaceuticos Rovi's value of 13.69 is 5.8% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own EV-to-EBITDA has ranged from 6.52 to 42.73 over the past decade. While the company's 10-year median is 18.25 vs. the industry median of 12.94, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.94, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current EV-to-EBITDA of 13.69 is 5.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Laboratorios Farmaceuticos Rovi. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current EV-to-EBITDA is 13.69, which is 25% below median its own 10-year median of 18.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current EV-to-EBITDA of 13.69. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current EV-to-EBITDA is 13.69, which is 25% below median its 10-year median of 18.25 and 5.8% above the Drug Manufacturers industry median of 12.94. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current EV-to-EBITDA is 13.69 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.
Key valuation signals for LABFF:
EV-to-EBITDA: 13.69 (25% below median its 10-year median of 18.25)
GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
Industry Position: 5.8% above the Drug Manufacturers median (#396 of 739)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for LABFF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
